Splash Beverage Group, Inc. (NYSE:SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX:AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products.

The investment represents a strategic capital allocation aligned with Splash's previously announced transformation into a cannabinoid-based health, wellness, and healthcare-focused platform company.

Splash believes Avicanna has assembled one of the most sophisticated cannabinoid healthcare platforms operating today and is uniquely positioned for the continued evolution of the medical cannabinoid market in the United States.